# US 2003/0077696 A1 · Human spamolytic polypeptide in glycosylated form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077696 A1
- Document ID: US20030077696A1
- Status: Published application
- Kind: A1
- Application number: 09/528,644
- Filed: 2000-03-20
- Published: 2003-04-24
- Earliest claimed: 1993-01-21
- Inventors: Lars Thim; Kjeld Norris; Fanny Norris; Soren Bjorn; Mogens Christensen; Per Franklin Nielsen
- Web page: https://patentgrep.com/patent/US20030077696A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A human spasmolytic polypeptide (HSP) having the amino acid SEQ ID NO:1, characterized by being in a glycosylated form.

## Claims

### Claim 1

Human spasmolytic polypeptide (HSP) which has the amino acid sequence
6 (SEQ ID NO:1) Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr
or a functionally equivalent homologue thereof, characterized by being in glycosylated form.

### Claim 2 (depends on 1)

HSP according to claim 1, characterized by being in N-glycosylated form.

### Claim 3 (depends on 1, 2)

HSP according to claim 1 or 2, which is glycosylated at Asn15.

### Claim 4 (depends on 3)

HSP according to claim 3, in which the glycosylated side chain contains at least one hexose unit.

### Claim 5 (depends on 4)

HSP according to claim 4, in which the glycosylated side chain contains at least one mannose unit, preferably at least five mannose units, most preferably at least ten mannose units.

### Claim 6 (depends on 5)

HSP according to claim 5, in which the glycosylated side chain contains 13-17 mannose units.

### Claim 7 (depends on 4)

HSP according to claim 4, which in addition is glycosylated with at least one unit of N-acetyl glucosamine (GlcNAc).

### Claim 8 (depends on 7)

HSP according to claim 7, which is glycosylated with (GlcNAc)2(Man)10-15.

### Claim 9 (depends on 1)

HSP according to claim 1, wherein Lys2 is replaced by Asn, Gln7 is replaced by Asn, Arg10 is replaced by Asn, Gly 20 is replaced by Thr or Ser, Gly23 is replaced by Asn, Ile 24 is replaced by Asn, Phe 36 is replaced by Asn, Asp 37 is replaced by Asn, Ser39 is replaced by Asn, Gln53 is replaced by Asn, Glu61 ia replaced by Asn, Asp64 is replaced by Asn, Arg66 is replaced by Thr or Ser, Gly69 is replaced by Thr or Ser, Gly72 is replaced by Asn, Ile 89 is replaced by Thr or Ser, Pro98 is replaced by Asn or Val101 is replaced by Thr or Ser, or a combination of two or more of these substitutions.

### Claim 10 (depends on 9)

HSP according to claim 9, wherein Asp64 is replaced by Asn, and wherein Arg66 is replaced by Thr or Ser.

### Claim 11 (depends on 9)

HSP according to claim 9, in which the glycosylated Asn contains at least one hexose unit.

### Claim 12 (depends on 11)

HSP according to claim 11, which is glycosylated with at least one mannose unit, preferably at least five mannose units, most preferably at least ten mannose units.

### Claim 13 (depends on 12)

HSP according to claim 12, which is glycosylated with 13-17 mannose units.

### Claim 14 (depends on 11)

HSP according to claim 11, which in addition is glycosylated with at least one unit of N-acetyl glucosamine (GlcNAc).

### Claim 15 (depends on 14)

HSP according to claim 14, which is glycosylated with (GlcNAc)2(Man)10-15.

### Claim 16

A variant of a spasmolytic polypeptide which is a fragment of human spasmolytic polypeptide (HSP) or porcine spasmolytic polypeptide (PSP) comprising at least one trefoil domain.

### Claim 17 (depends on 16)

A variant according to claim 16, which comprises at least a sequence of amino acids from position 8 to 46 or from position 58 to 95.

### Claim 18 (depends on 16, 17)

A variant according to claim 16 or 17, wherein Asn15 is substituted by another amino acid, e.g. Asp or Glu.

### Claim 19 (depends on 16, 17)

A variant according to claim 16 or 17, wherein Thr17 is substituted by another amino acid except Ser, e.g. Ala.

### Claim 20 (depends on 16, 17)

A variant according to claim 16 or 17, wherein Arg10 is replaced by Asn, Gly 20 is replaced by Thr or Ser, Gly23 is replaced by Asn, Ile 24 is replaced by Asn, Phe 36 is replaced by Asn, Asp 37 is replaced by Asn, Ser39 is replaced by Asn, Glu61 ia replaced by Asn, Asp64 is replaced by Asn, Arg66 is replaced by Thr or Ser, Gly69 is replaced by Thr or Ser, or Gly72 is replaced by Asn, or a combination of two or more of these substitutions.

### Claim 21

A method of preparing a spasmolytic polypeptide in at least 60% glycosylated form, wherein a host cell transformed with a DNA fragment encoding a spasmolytic polypeptide and capable of providing glycosylation of said spasmolytic polypeptide is cultured under conditions permitting production of said spasmolytic polypeptide and recovering the resulting spasmolytic polypeptide from the culture.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the host cell is a fungal cell such as a yeast cell, e.g. a strain of Saccharomyces cerevisiae, or a filamentous fungus cell, e.g. a strain of Aspergillus, such as Aspergillus oryzae.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A pharmaceutical composition comprising HSP according to any of claims 1-15 together with a pharmaceutically acceptable carrier or excipient.

### Claim 24 (depends on 16, 17, 18, 19, 20)

A pharmaceutical composition comprising a variant spasmolytic polypeptide according to any of claims 16-20 together with a pharmaceutically acceptable carrier or excipient.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

Use of HSP according to any of claims 1-15 for the manufacture of a medicament for the prophylaxis or treatment of gastrointestinal disorders.

### Claim 26 (depends on 16, 17, 18, 19, 20)

Use of a variant spasmolytic polypeptide according to any of claims 16-20 for the manufacture of a medicament for the prophylaxis or treatment of gastrointestinal disorders.
